| 20.31 Delayed Data As of Mar 19 |  +0.21 / +1.04%Today’s Change | 17.83 Today|||52-Week Range 21.30 | +8.32% Year-to-Date |
| Novartis' (NVS) Alcon Acquired PowerVision for $285 Million Mar 18 / Zacks.com - Paid Partner Content | Top Research Reports for Microsoft, Mastercard & General Electric Mar 08 / Zacks.com - Paid Partner Content |
| GlaxoSmithKline (GSK) Stock Sinks As Market Gains: What You Should Know Mar 12 / Zacks.com - Paid Partner Content | Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy Mar 07 / Zacks.com - Paid Partner Content |
| Should Value Investors Pick GlaxoSmithKline (GSK) Stock Now? Mar 12 / Zacks.com - Paid Partner Content | Roche's (RHHBY) sNDA for Flu Candidate Accepted by the FDA Mar 06 / Zacks.com - Paid Partner Content |
| Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy Mar 08 / Zacks.com - Paid Partner Content |
| Previous close | 20.10 |
| Today’s open | 19.79 |
| Day’s range | 19.79 - 20.31 |
| Volume | 535 |
| Average volume (3 months) | 6,126 |
| Market cap | $99.8B |
| Earnings growth (last year) | -- |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +5.72% |
| P/E ratio | 13.8 |
| Price/Sales | 2.30 |
| Price/Book | 17.82 |
| No competitors data available. |
| Next reporting date | -- |
| EPS forecast (this quarter) | -- |
| Annual revenue (last year) | $41.1B |
| Annual profit (last year) | $4.8B |
| Net profit margin | 11.75% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chief Executive Officer & Executive Director Emma Walmsley |
Chief Financial Officer & Executive Director Simon Paul Dingemans |
Corporate headquarters Brentford, Greater London |
